サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1786453

DNA修復薬の世界市場

DNA Repair Drugs

出版日
ページ情報
英文 217 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.50円
DNA修復薬の世界市場
出版日: 2025年08月08日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 217 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

DNA修復薬の世界市場は2030年までに米国で195億米ドルに達する見込み

2024年に83億米ドルと推定されるDNA修復薬の世界市場は、分析期間2024-2030年にCAGR 15.2%で成長し、2030年には195億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである標的療法は、CAGR 17.2％を記録し、分析期間終了までに85億米ドルに達すると予想されます。ホルモン療法分野の成長率は、分析期間中CAGR 11.8%と推定されます。

米国市場は22億米ドルと推定、中国はCAGR14.2％で成長予測

米国のDNA修復薬市場は2024年に22億米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR14.2%で推移し、2030年までに30億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ14.3％と12.9％と予測されています。欧州では、ドイツがCAGR 10.9%で成長すると予測されています。

世界のDNA修復薬市場- 主要動向と促進要因のまとめ

DNA修復機構を標的とすることががん治療のパラダイムを再定義する？

DNA修復機構の研究は、治療的に利用可能ながん細胞の脆弱性を明らかにすることにより、腫瘍学に革命をもたらしました。ゲノムの完全性の維持に関与する特定の酵素や経路を標的とするDNA修復薬は、この変革の最前線にあります。がん細胞は、その主要な修復経路の欠陥のために、しばしば代替DNA修復メカニズムに大きく依存します。合成致死として知られるこの概念は、PARP（ポリADPリボースポリメラーゼ）阻害剤のような、FDAに承認されたいくつかの薬剤の基礎となっており、BRCA変異卵巣がん、乳がん、膵臓がん、前立腺がんの治療において顕著な有効性を示しています。DNA修復阻害剤の有望性は、正常細胞を温存しながら腫瘍細胞を選択的に死滅させる能力にあり、化学療法にありがちな標的外毒性を軽減します。PARP以外にも、ATM、ATR、DNA-PK、CHK1/2、POLQなど、DNA損傷に対する細胞反応に重要な役割を果たす様々な標的を積極的に探索しています。これらの新たな治療法は、免疫療法、放射線療法、伝統的な化学療法と並んで、単剤療法および併用療法として評価されています。DNA修復を標的とした治療法の精度と個別化により、個人のゲノムプロファイルに合わせたより効果的な治療戦略が可能になりつつあります。そのため、バイオマーカー主導の薬剤開発は、この分野の中心的な役割を担っており、コンパニオン診断が最も効果が期待できる患者の同定に用いられています。DNA損傷応答（DDR）ネットワークの理解が深まるにつれて、DNA修復薬は、がんの治療方法を再定義しています。すなわち、万能モデルから、高度に標的化されたメカニズム特異的アプローチへと移行し、がん学の新時代を迎えています。

ゲノミクスとバイオマーカー科学の進歩は、医薬品開発をどのように後押ししているか？

ゲノミクス、シークエンシング、分子診断における技術的進歩は、腫瘍におけるDNA修復欠損の正確な同定を可能にすることで、DNA修復薬の開発と臨床応用を推進しています。BRCA1/2、ATM、PALB2、その他の相同組換え修復（HRR）およびミスマッチ修復（MMR）経路の構成要素などの遺伝子における変異を検出するために、ハイスループットシーケンスおよび次世代シーケンシング（NGS）プラットフォームが現在広く使用されています。このような洞察により、臨床医や研究者は遺伝的構成に基づいて患者を層別化し、治療反応をより正確に予測することができます。さらに、"BRCAness "や相同組換え欠損（HRD）スコアなどの新しいゲノムシグネチャーの発見により、DNA修復薬の適格基準は生殖細胞系列のBRCA遺伝子変異だけにとどまらない広がりを見せています。循環腫瘍DNA（ctDNA）を検出するリキッドバイオプシーもまた、リアルタイムで治療反応性と抵抗性をモニターする低侵襲ツールとして人気を集めています。バイオマーカーに誘導された医薬品開発は、製薬会社にとって重要な戦略となっており、豊富な患者集団とより高い成功確率で、よりスマートな臨床試験をデザインするのに役立っています。さらに、CRISPR-Cas9遺伝子編集は、特定のDNA修復遺伝子の役割とがんの進行への寄与をよりよく理解するために前臨床モデルで使用されており、新たな治療標的の同定への道を開いています。また、インシリコ・モデリングとAI主導の創薬プラットフォームは、より高い選択性と効力を持つ低分子阻害剤の同定を加速させています。このような技術的相乗効果は、薬剤設計を洗練させるだけでなく、より強固な臨床パイプラインを可能にし、分子レベルで定義された腫瘍サブタイプに合わせた新世代のDNA修復薬の舞台を整えつつあります。

がん以外の治療領域の拡大が市場の可能性を広げる？

DNA修復薬の主な用途は依然としてがん治療であるが、これらの薬剤の潜在的な治療範囲は、がん以外の様々な病態にも拡大しつつあり、市場の可能性を大きく広げています。DNA修復機構は、老化、炎症、神経変性など、ゲノムの不安定性が疾患の発症や進行に関与する領域で重要な役割を果たしています。アルツハイマー病、パーキンソン病、ハンチントン病などの神経変性疾患では、DNA損傷応答経路の欠陥が神経細胞死や認知機能低下の一因であることを示唆する証拠が増えています。研究者たちは、DNA修復酵素を調節することによって、病気の進行を遅らせたり、神経保護を強化することができるかどうかを調査しています。同様に、自己免疫疾患や運動失調症性脊髄拡張症やファンコニー貧血のような稀な遺伝性疾患も、DNA修復酵素の欠損によって特徴づけられるが、DNA修復酵素を調節する新たな治療法として注目されています。さらに、放射線被曝は、がん治療によるものであれ、環境的なものであれ、DNA損傷を誘発するので、DNA修復促進剤を開発することで、健康な組織を保護したり、長期的な影響を緩和したりすることができます。製薬会社は、がん領域では阻害剤として、その他の疾患では保護剤として、適用方法に応じて両用できる分子を模索しています。このような治療上の柔軟性がDNA修復薬候補の商業的魅力を高め、より広範な研究開発投資を促しています。特に健康長寿の柱としてゲノムの維持に焦点を当てた老化研究の台頭は、潜在的な介入ポイントとしてDNA修復経路に注目させています。科学界がDNA損傷、慢性疾患、細胞老化の相互関連性を探求し続ける中、DNA修復薬の関連性はがんをはるかに超えて拡大し、価値の高い臨床応用の数々を解き放ちつつあります。

DNA修復薬市場の成長を促進する要因とは？

DNA修復薬市場の成長は、科学的イノベーション、精密医療、進化する治療戦略に深く根ざしたいくつかの要因によってもたらされます。主な促進要因は、世界のがんの有病率の増加であり、より標的を絞った毒性の低い治療法に対する需要が高まっています。DNA修復阻害剤、特にPARP阻害剤は、BRCA変異腫瘍や相同組換え欠損腫瘍の生存予後を改善することにすでに成功を示しており、採用率の上昇と新たな適応症の獲得につながっています。個別化医療の推進も重要な要因の一つであり、臨床医はDNA修復遺伝子に変異があり、これらの治療が有効な患者を特定するために、分子プロファイリングを利用するようになってきています。シークエンシング技術やコンパニオン診断薬の進歩により、このような精密ターゲティングがより現実的で費用対効果の高いものになってきています。さらに、製薬業界では併用療法に重点を置く動きが拡大しており、DNA修復薬は免疫チェックポイント阻害剤、化学療法、放射線療法と併用して有効性を高め、耐性を克服するために使用されており、市場成長において重要な役割を果たしています。ATR、ATM、DNA-PK、その他のDDR標的の阻害剤を探索する臨床試験の数が増加していることは、開発パイプラインが強固で成長していることを反映しています。さらに、バイオテクノロジー新興企業と大手製薬企業との戦略的提携により、初期段階の研究から実行可能な治療候補薬への転換が加速しています。規制当局もまた、ファスト・トラック指定、画期的治療薬の承認、承認薬の適応拡大などを通じてイノベーションを支援しています。市販後試験から得られた現実のエビデンスの出現は、これらの治療法の長期的な有用性を検証し、償還の決定を導くのに役立っています。最後に、腫瘍学と加齢研究に対する公的および民間投資は、DNA修復生物学の継続的な研究のための肥沃な環境を作り出し、市場の勢いをさらに加速させています。これらの相互関連的な推進力により、DNA修復薬は腫瘍学およびそれ以外の領域における次世代治療戦略の礎石として総体的に位置づけられています。

セグメント

乳がん治療薬（標的療法、ホルモン療法、化学療法、免疫療法）、乳がん治療薬のがんタイプ（ホルモン受容体タイプ、HER2+タイプ）、乳がん治療薬の流通チャネル（病院薬局、小売薬局、その他の流通チャネル）

調査対象企業の例

  • AbbVie Inc.
  • Agios Pharmaceuticals, Inc.
  • Allarity Therapeutics A/S
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Boehringer Ingelheim GmbH
  • Breakpoint Therapeutics
  • Bristol-Myers Squibb Company
  • Clovis Oncology
  • Eli Lilly and Company
  • FoRx Therapeutics
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Lantern Pharma Inc.
  • Luciole Pharmaceuticals
  • Merck & Co., Inc.
  • Novartis AG

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP30559

Global DNA Repair Drugs Market to Reach US$19.5 Billion by 2030

The global market for DNA Repair Drugs estimated at US$8.3 Billion in the year 2024, is expected to reach US$19.5 Billion by 2030, growing at a CAGR of 15.2% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 17.2% CAGR and reach US$8.5 Billion by the end of the analysis period. Growth in the Hormonal Therapy segment is estimated at 11.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.2 Billion While China is Forecast to Grow at 14.2% CAGR

The DNA Repair Drugs market in the U.S. is estimated at US$2.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.0 Billion by the year 2030 trailing a CAGR of 14.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.3% and 12.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.9% CAGR.

Global DNA Repair Drugs Market - Key Trends & Drivers Summarized

Is Targeting DNA Repair Mechanisms Redefining Cancer Therapy Paradigms?

The study of DNA repair mechanisms has revolutionized oncology by uncovering vulnerabilities in cancer cells that can be therapeutically exploited. DNA repair drugs, which target specific enzymes and pathways involved in maintaining genomic integrity, are at the forefront of this transformation. Cancer cells often rely heavily on alternative DNA repair mechanisms due to defects in their primary repair pathways-making them uniquely sensitive to targeted inhibition. This concept, known as synthetic lethality, is the foundation for several FDA-approved drugs, such as PARP (poly ADP-ribose polymerase) inhibitors, which have demonstrated remarkable efficacy in treating BRCA-mutated ovarian, breast, pancreatic, and prostate cancers. The promise of DNA repair inhibitors lies in their ability to selectively kill tumor cells while sparing normal cells, reducing off-target toxicity commonly associated with chemotherapy. Beyond PARP, the industry is actively exploring a range of targets including ATM, ATR, DNA-PK, CHK1/2, and POLQ, each playing vital roles in the cellular response to DNA damage. These emerging therapies are being evaluated as both monotherapies and combination regimens alongside immunotherapy, radiation, and traditional chemotherapy. The precision and personalization of DNA repair-targeted therapies are enabling more effective treatment strategies tailored to individual genomic profiles. Biomarker-driven drug development is thus central to this field, as companion diagnostics are used to identify patients most likely to benefit. As understanding of the DNA damage response (DDR) network deepens, DNA repair drugs are redefining the way cancers are treated-shifting from a one-size-fits-all model to a highly targeted, mechanism-specific approach that marks a new era in oncology.

How Are Advances in Genomics and Biomarker Science Powering Drug Development?

Technological advancements in genomics, sequencing, and molecular diagnostics are driving the development and clinical application of DNA repair drugs by enabling precise identification of DNA repair deficiencies in tumors. High-throughput sequencing and next-generation sequencing (NGS) platforms are now widely used to detect mutations in genes like BRCA1/2, ATM, PALB2, and other components of the homologous recombination repair (HRR) and mismatch repair (MMR) pathways. These insights allow clinicians and researchers to stratify patients based on their genetic makeup and predict treatment response more accurately. Furthermore, the discovery of novel genomic signatures such as "BRCAness" or homologous recombination deficiency (HRD) scores is expanding the eligibility criteria for DNA repair drugs beyond just germline BRCA mutations. Liquid biopsies, which detect circulating tumor DNA (ctDNA), are also gaining traction as minimally invasive tools to monitor treatment response and resistance in real time. Biomarker-guided drug development has become a key strategy for pharmaceutical companies, helping them design smarter clinical trials with enriched patient populations and higher success probabilities. Moreover, CRISPR-Cas9 gene editing is being used in preclinical models to better understand the role of specific DNA repair genes and their contribution to cancer progression, paving the way for the identification of new therapeutic targets. In silico modeling and AI-driven drug discovery platforms are also accelerating the identification of small-molecule inhibitors with higher selectivity and potency. These technological synergies are not only refining drug design but also enabling more robust clinical pipelines, setting the stage for a new generation of DNA repair drugs tailored to molecularly defined tumor subtypes.

Is the Expanding Therapeutic Scope Beyond Cancer Broadening Market Potential?

While oncology remains the primary application for DNA repair drugs, the potential therapeutic scope of these agents is expanding to include a variety of non-oncological conditions, which is significantly broadening the market’s potential. DNA repair mechanisms play a crucial role in aging, inflammation, and neurodegeneration-areas where genomic instability contributes to disease onset and progression. In neurodegenerative disorders like Alzheimer’s, Parkinson’s, and Huntington’s disease, growing evidence suggests that defects in DNA damage response pathways may contribute to neuronal death and cognitive decline. Researchers are investigating whether modulating DNA repair enzymes could slow disease progression or enhance neuroprotection. Similarly, autoimmune diseases and rare genetic disorders such as ataxia-telangiectasia and Fanconi anemia-characterized by inherent DNA repair deficiencies-are emerging as new therapeutic frontiers for DNA repair modulation. Moreover, radiation exposure, whether from cancer therapy or environmental sources, induces DNA damage, and DNA repair enhancers could be developed to protect healthy tissues or mitigate long-term effects. Pharmaceutical companies are exploring dual-use molecules that serve both as inhibitors in oncology and as protectants in other diseases, depending on how they are applied. This therapeutic flexibility increases the commercial attractiveness of DNA repair drug candidates, encouraging broader R&D investment. The rise of aging research, particularly focused on genome maintenance as a pillar of healthy longevity, is drawing attention to DNA repair pathways as potential intervention points. As the scientific community continues to explore the interconnectedness of DNA damage, chronic disease, and cellular aging, the relevance of DNA repair drugs is expanding far beyond cancer, unlocking a multitude of high-value clinical applications.

What Are the Core Drivers Fueling Growth in the DNA Repair Drugs Market?

The growth in the DNA repair drugs market is driven by several factors deeply rooted in scientific innovation, precision medicine, and evolving therapeutic strategies. A major driver is the growing prevalence of cancer worldwide, which is increasing demand for more targeted and less toxic therapies. DNA repair inhibitors, particularly PARP inhibitors, have already shown success in improving survival outcomes in BRCA-mutated and homologous recombination-deficient tumors, leading to rising adoption and new indications. The push toward personalized medicine is another key factor-clinicians are increasingly using molecular profiling to identify patients with DNA repair gene mutations who can benefit from these therapies. Advances in sequencing technologies and companion diagnostics are making such precision targeting more feasible and cost-effective. Additionally, the pharmaceutical industry’s expanding focus on combination therapies is playing a critical role in market growth, with DNA repair drugs being used alongside immune checkpoint inhibitors, chemotherapy, and radiation to enhance efficacy and overcome resistance. The increasing number of clinical trials exploring inhibitors of ATR, ATM, DNA-PK, and other DDR targets reflects a robust and growing development pipeline. Moreover, strategic collaborations between biotech startups and large pharmaceutical companies are accelerating the translation of early-stage research into viable therapeutic candidates. Regulatory bodies are also supporting innovation through fast-track designations, breakthrough therapy approvals, and expanded label indications for approved drugs. The emergence of real-world evidence from post-marketing studies is helping validate the long-term benefits of these treatments and guiding reimbursement decisions. Finally, public and private investments in oncology and aging research are creating a fertile environment for continued exploration of DNA repair biology, further propelling market momentum. These interconnected drivers are collectively positioning DNA repair drugs as a cornerstone of next-generation therapeutic strategies across oncology and beyond.

SCOPE OF STUDY:

The report analyzes the DNA Repair Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Breast Cancer Drugs Therapy (Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy, Immunotherapy Therapy); Breast Cancer Drugs Cancer Type (Hormone Receptor Type, HER2+ Type); Breast Cancer Drugs Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

  • AbbVie Inc.
  • Agios Pharmaceuticals, Inc.
  • Allarity Therapeutics A/S
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Boehringer Ingelheim GmbH
  • Breakpoint Therapeutics
  • Bristol-Myers Squibb Company
  • Clovis Oncology
  • Eli Lilly and Company
  • FoRx Therapeutics
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Lantern Pharma Inc.
  • Luciole Pharmaceuticals
  • Merck & Co., Inc.
  • Novartis AG

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • DNA Repair Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advances in Cancer Genomics Throw the Spotlight on DNA Repair Pathways as Therapeutic Targets
    • Success of PARP Inhibitors Propels Growth and Validates the DNA Repair Drug Development Model
    • Rising Prevalence of BRCA and HRD-Related Cancers Strengthens Business Case for Synthetic Lethality-Based Therapies
    • Expansion of Companion Diagnostics Accelerates Adoption of Biomarker-Guided DNA Repair Treatments
    • Integration of DNA Repair Drugs into Combination Therapy Regimens Spurs Broader Oncology Use Cases
    • Growing Focus on Tumor-Specific Vulnerabilities Drives Development of Novel DDR (DNA Damage Response) Inhibitors
    • Emerging Targets Beyond PARP, Including ATR, ATM, DNA-PK, and POLQ, Expand Addressable Therapeutic Pipeline
    • Increased Investment in Precision Oncology Programs Fuels R&D Activity in DNA Repair Modulators
    • Use of CRISPR and Functional Genomics in Drug Discovery Enhances Target Validation and Pipeline Innovation
    • Real-World Evidence and Post-Market Data Strengthen Confidence in Long-Term Clinical Benefits
    • Growing Applications in Prostate, Pancreatic, and Ovarian Cancers Drive Indication Expansion
    • Potential Utility in Non-Oncological Conditions Opens New Growth Frontiers for DNA Repair Modulation
    • Global Rise in Personalized Medicine Initiatives Generates Sustained Demand for Genomic Repair Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World DNA Repair Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for DNA Repair Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for DNA Repair Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for DNA Repair Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Chemotherapy Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Chemotherapy Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Chemotherapy Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Immunotherapy Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Immunotherapy Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Immunotherapy Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hormone Receptor Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hormone Receptor Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hormone Receptor Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for HER2+ Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for HER2+ Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for HER2+ Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • DNA Repair Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • JAPAN
    • DNA Repair Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CHINA
    • DNA Repair Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • EUROPE
    • DNA Repair Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for DNA Repair Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for DNA Repair Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for DNA Repair Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • FRANCE
    • DNA Repair Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • GERMANY
    • DNA Repair Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • DNA Repair Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Rest of Europe 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Rest of Europe 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Europe 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • DNA Repair Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Asia-Pacific 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Asia-Pacific 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Asia-Pacific 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of World 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of World 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of World Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of World Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of World 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION